- Opinion
- [Reporter's view] A plan to expand the reference country
- by Lee, Tak-Sun Dec 8, 2022 06:05am
- The pharmaceutical industry is strongly opposed to the government's plan to expand drug price reference countries. Although the Ministry of Health and Welfare says it has gone through a sufficient discussion process, the industry is strongly criticizing it as a one-sided push. The revision of the HIRA's administrative notice on the 21st of la
- Opinion
- [Reporter's view] Opinions surrounding the multinational ERP
- by Eo, Yun-Ho Nov 29, 2022 05:54am
- Every office worker has a fear of restructuring. Companies have no choice but to consider layoffs in terms of cost reduction when circumstances are difficult. This year, a number of multinational pharmaceutical companies have either cut their jobs or are in progress. In the case of these multinational pharmaceutical companies, the number of p
- Opinion
- [Reporter's view]There should be no recurrence of COVID kit
- by Lee, Hye-Kyung Nov 28, 2022 05:50am
- Demand for self-examination kits is increasing rapidly as Twindemic, where COVID-19 and seasonal flu are prevalent at the same time, becomes a reality. According to the pharmacy site data analysis service Care Insight (www.careinsight.co.kr), 12,629 self-kits were sold at 396 pharmacies in the 47th week of this year (11/13-19), with daily sal
- Opinion
- [Reporter's view] Godex benefit adequacy will be further di
- by Lee, Tak-Sun Nov 25, 2022 06:05am
- At the Health Insurance Policy Deliberation Committee held on the 23rd, it was decided to further discuss the appropriateness of the salaries of Godex and Imotun at the next deliberation committee. Although the HIRA Drug Benefit Evaluation Committee recognized the appropriateness of the benefit, the final organization, the Health Insurance P
- Opinion
- [Reporter's view] Poor COVID-19 vaccine inducement
- by Nov 22, 2022 06:04am
- "Did you get the COVID-19 vaccine in winter? Mom and dad are the ones who should be vaccinated" The mother answered in a casual manner. "It's okay. I'm in my 60s, so I don't have to get it." "What are you talking about? You have hyperlipidemia. Get it right quickly." "It's okay. I think it'll pass lightly even if I get COVID-19." But will par
- Opinion
- [Reporter's view] Generic drugs can't be me-too drug
- by Kim, Jin-Gu Nov 17, 2022 05:54am
- Controversy is brewing over the government's push to replace the term "generic" with me-too-drug. The KPBMA and the Korean Pharmaceutical Association immediately objected. They stress that it is not enough to contain all the meanings of the term generic in the term copy drug. The backlash from the pharmaceutical industry seems reasonable. Thi
- Opinion
- [Reporter's view] APAP price increase should be quick
- by Lee, Tak-Sun Nov 16, 2022 06:10am
- The government is rushing to raise the upper limit of Acetaminophen which supply and demand are unstable due to COVID-19. The government's plan is to end the review and negotiations as early as this month to reflect the increase plan next month. As the supply and demand of cold medicine continue throughout the year and a large-scale COVID-
- Opinion
- [Reporter’s View] Advanced new drugs, reimb, and patients
- by Eo, Yun-Ho Nov 15, 2022 05:39am
- Some drugs can be prescribed regardless of mutation or receptor status at certain stages of a disease. Other drugs can be prescribed regardless of disease if a certain gene mutation is identified in the patient. As such, the field of pharmaceuticals is evolving at a rapid pace. New drugs that are no longer attached to a specific disease a
- Opinion
- [Reporter's view] COVID-19 demand has disappeared
- by Nov 10, 2022 05:45am
- The boom of pharmaceutical companies, which had benefited from COVID-19, has subsided since the third quarter. Representatively, Roche Group suffered a sharp drop in sales of diagnostic kits and treatments in the third quarter. Roche Group supplies Actemra and Ronapreve, a treatment for COVID-19, and Roche Diagnostics manufactures a COVID-19
- Opinion
- [Reporter’s View] Reimb for SLGT-2i combo still in discussi
- by Eo, Yun-Ho Nov 4, 2022 05:39am
- The agenda has been in the last stages of review for 5 months. At this pace, discussions on expanding reimbursement of SGLT-2 inhibitors as combination therapy may again be passed on to the next year. The discussion on expanding reimbursement of SGLT-2 inhibitors as combination therapy has remained stagnant for a long time. After no progr
